Nasdaq: ARWRArrowhead Pharmaceuticals

    Arrowhead Pharmaceuticals Q4 FY2026 Results: Net Loss $724 Million on Revenue of $451 Million

    • US stocks
    • Earnings
    • Health Care
    Assorted tablets and capsules in white, pink, yellow, blue and orange
    freestocks.org freestocks, via Wikimedia Commons (CC0). Illustrative image.

    Arrowhead Pharmaceuticals (Nasdaq: ARWR) reported results for its 2026 fiscal year ended 30 Sep 2026, with GAAP revenue of $450.8 million and a GAAP net loss attributable to the company of $724.2 million, it said on 12 Nov 2026. Diluted loss per share (GAAP) was $5.11. The release gives no adjusted (non-GAAP) figures.

    Key highlights

    • Revenue (GAAP): $450.8 million, down 45.6% YoY
    • Net loss attributable to the company (GAAP): $724.2 million, against $1.6 million a year earlier
    • Diluted loss per share (GAAP): $5.11, against $0.01 a year earlier
    • Total cash resources: $1.19 billion at 30 Sep 2026
    • New senior secured term loan: $400.0 million at SOFR plus 5.50%

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ4 FY2026Q4 FY2025YoY
    Revenue450.8829.4-45.6%
    -707.298.3n/a
    -724.2-1.6-44302.6%
    Diluted EPS ($)-5.11-0.01-51000.0%

    Figures are in $ million except EPS; YoY compares with Q4 FY2025. Q4 FY2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are the release's own comparatives, not cross-checked against SEC XBRL data. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    The table compares the release's fiscal 2026 year with its fiscal 2025 year, as the release states them. Revenue fell 45.6%, to $450.8 million from $829.4 million. Operating income was -$707.2 million, against $98.3 million a year earlier.

    Operating margin was -156.9% of revenue, against 11.9% a year earlier, and net loss was -160.6% of revenue, against -0.2%. The release does not give a three-month figure for the fourth quarter, so the table's figures are for the full fiscal year.

    Revenue fell and the operating loss widened

    Revenue was $450.8 million for fiscal 2026, against $829.4 million for fiscal 2025. The company reported an operating loss of $707.2 million, against operating income of $98.3 million a year earlier.

    The release lists research and development expenses of $739.1 million, against $607.2 million, and selling, general and administrative expenses of $202.0 million, against $123.9 million. It also lists an acquired Priority Review Voucher cost of $215.0 million, which the company says it retains. The release does not state a reason for the change in these lines.

    Refinancing replaces a 15% facility

    The company refinanced its credit facility with Sixth Street and set up a new $400 million senior secured term loan facility. It carries an interest rate of SOFR plus 5.50%, compared with an annual rate of 15% on the retired facility, and matures in November 2031.

    The company says it negotiated a $68 million discount on the prepayment amount of the retired facility and that the new facility removes required prepayments or sweeps from certain transactions. At 30 Sep 2026 the credit facility balance was $195.4 million and convertible notes, net, were $683.5 million.

    The company says its Board approved on 9 Nov 2026 a change in fiscal year end from 30 September to 31 December, effective 1 Jan 2027.

    Launch and trial steps the company reports

    The company says new-to-brand REDEMPLO prescriptions grew 63% quarter over quarter, with 950 cumulative since launch at quarter end. It says it submitted an sNDA to the FDA for plozasiran in severe hypertriglyceridemia and prepares for a potential U.S. launch in the second quarter of 2027, pending regulatory review and approval.

    The company says it completed enrollment in the Phase 3 YOSEMITE trial of zodasiran, with target enrollment raised from 60 to 70 patients, and expects the trial to be completed in mid-2027.

    Inference

    The release reports a net loss attributable to the company of $724.2 million, and diluted loss per share of $5.11 on 141,631 thousand weighted-average diluted shares. It gives total cash resources of $1.19 billion and shares outstanding of 141,290 thousand at 30 Sep 2026. It does not state any share repurchase or dividend.

    The release does not give cash flow from operations, free cash flow or any financial guidance for fiscal 2027, and it does not state the effect of the fiscal year change on reported results.

    The next dated steps the company gives are a transition report on Form 10-QT covering 1 Oct 2026 to 31 Dec 2026, and completion of the YOSEMITE trial in mid-2027.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts